EAM Investors LLC Reduces Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

EAM Investors LLC lessened its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 13.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 235,813 shares of the biotechnology company’s stock after selling 36,821 shares during the period. EAM Investors LLC owned 0.10% of ADMA Biologics worth $4,044,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of ADMA. Vanguard Group Inc. grew its stake in shares of ADMA Biologics by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company’s stock valued at $312,109,000 after buying an additional 80,302 shares during the period. Geode Capital Management LLC lifted its holdings in ADMA Biologics by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company’s stock valued at $93,187,000 after acquiring an additional 50,399 shares during the last quarter. Renaissance Technologies LLC grew its position in ADMA Biologics by 2.8% in the fourth quarter. Renaissance Technologies LLC now owns 3,769,888 shares of the biotechnology company’s stock worth $64,654,000 after acquiring an additional 102,692 shares during the period. Perpetual Ltd acquired a new stake in ADMA Biologics during the fourth quarter worth $62,300,000. Finally, Lord Abbett & CO. LLC purchased a new stake in ADMA Biologics in the third quarter valued at $61,858,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $22.15 on Wednesday. ADMA Biologics, Inc. has a fifty-two week low of $5.91 and a fifty-two week high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The company has a 50 day moving average price of $17.96 and a 200 day moving average price of $18.19. The stock has a market capitalization of $5.24 billion, a P/E ratio of 79.11 and a beta of 0.53.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.